References
1. Diller L., Chow E.J., Gurney J.G., Hudson M.M., Kadin-Lottick N.S., Kawashima T.I., et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009; 27 (14): 2339-55. DOI: https://doi.org/10.1200/JCO.2008.21.1953 PMID: 19364955; PMCID: PMC 2677922
2. Bobrova E.I., Pavlova M.G., Sotnikov V.M., Pronin V.S., Fadeev V.V. Hypopituitarism after radiotherapy for childhood malignant tumors. Klinicheskaya i eksperimental'naya tireodologiya [Clinical and Experimental Thyroidology]. 2013; 9 (3): 15-20. DOI: https://doi.org/10.14341/ket20139315-20 (in Russian)
3. Hodgkin Lymphoma. Clinical recommendations. Sovremennaya onkologiya [Modern Oncology]. 2020; 22 (2): 6-33. DOI: https://doi.org/10.26442/18151434.2020.2.200132 (in Russian)
4. Bystrova O.V., Kalugina A.S., Cybatova E.V., Tapil'skaya N.I., Dinikina Yu.V., Lisjanskaja A.S., et al. Fertility preservation in cancer patients. Prakticheskaya onkologiya [Practical Oncology]. 2009; 10 (4): 245-53. (in Russian)
5. Fazlyeva E.A., Mironova M.P., Faskhutdinova G.G., Islamgulov D.V. Current fertility preservation methods in women with cancer. Kreativnaya khirurgiya i onkologiya [Creative Surgery and Oncology]. 2012; (3): 84-9. DOI: https://doi.org/10.24060/2076-3093-2012-0-3-84-89 (in Russian)
6. Shmakov R.G., Abubakirov A.N., Volochaeva M.V., Demina E.A. Fertility preservation in oncology patients. Medicamente. 2016; (2): 11-7. (in Russian)
7. Braverman L.E., Utiger R.D. Werner & Ingbar's the Thyroid. 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2000.
8. Boomsma M.J., Bijl H.P., Langendijk J.A. Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review. Radiother Oncol. 2011; 99 (1): 1-5. DOI: https://doi.org/10.1016/j.radonc.2011.03.002 PMID: 21459468.
9. Vivanco M., Dalle J.H., Alberti C., Lescoeur B., Yakouben K., Carel J.C., et al. Malignant and benign thyroid nodules after total body irradiation preceding hematopoietic cell transplantation during childhood. Eur J Endocrinol. 2012; 167 (2): 225-33. DOI: https://doi.org/10.1530/EJE-12-0073 PMID: 22619350.
10. Hancock S.L., Cox R.S., McDougall I.R. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991; 325 (9): 599-605. DOI: https://doi.org/10.1056/NEJM199108293250902 PMID: 1861693.
11. Sklar C., Whitton J., Mertens A., Stovall M., Green D., Marina N., et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000; 85 (9): 3227-32. DOI: https://doi.org/10.1210/jcem.85.9.6808 PMID: 10999813.
12. Bobrova E.I., Pavlova M.G., Sotnikov V.M., Parkhomenko R.A., Fadeev V.V. Hypothyroidism due to cranial and craniospinal Irradiation. Klinicheskaya i eksperimental'naya tireodologiya [Clinical and Experimental Thyroidology]. 2013; 9 (4): 15-9. DOI: https://doi.org/10.14341/ket20139415-19 (in Russian)
13. van Santen H.M., de Kraker J., van Eck B.L., de Vijlder J.J., Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131) I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002; 94 (7): 2081-9. DOI: https://doi.org/10.1002/cncr.10447 PMID: 11932913
14. Grenier G., Van Sande J., Willems C., Neve P., Dumont J.E. Effects of microtubule inhibitors and cytochalasin B on thyroid metabolism in vitro. Biochimie. 1975; 57 (3): 337-41. DOI: https://doi.org/10.1016/s0300-9084(75)80309-9 PMID: 167874
15. Massart C., Le Tellier C., Lucas C., Gibassier J., Leclech G., Nicol M. Effects of cisplatin on human thyrocytes in monolayer or follicle culture. J Mol Endocrinol. 1992; 8 (3): 243-8. DOI: https://doi.org/10.1677/jme.0.0080243 PMID: 1321636
16. van Santen H.M., de Kraker J., van Eck B.L., de Vijlder J.J., Vulsma T. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131) I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer. 2002; 94 (7): 2081-9. DOI: https://doi.org/10.1002/cncr.10447 PMID: 11932913
17. Quach A., Ji L., Mishra V., Sznewajs A., Veatch J., Huberty J., et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer. 2011; 56 (2): 191-201. DOI: https://doi.org/10.1002/pbc.22767 PMID: 20830775; PMCID: PMC 3006009.
18. Clement S.C., van Rijn R.R., van Eck-Smit B.L., van Trotsenburg A.S., Caron H.N., Tytgat G.A., et al. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Eur J Nucl Med Mol Imaging. 2015; 42 (5): 706-15. DOI: https://doi.org/10.1007/s00259-014-2967-4 PMID: 25512056.
19. Massimino M., Podda M., Gandola L., Pignoli E., Seregni E., Morosi C., et al. Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study. Front Med. 2021; 15 (1): 101-7. DOI: https://doi.org/10.1007/s11684-020-0752-2 PMID: 32794013.
20. Harris J., Almarzouki H., Barber B., Scrimger R., Romney J., O'Connell D., et al. Free thyroid transfer: a novel procedure to prevent radiation-induced hypothyroidism. Int J Radiat Oncol Biol Phys. 2016; 96 (1): 42-5. DOI: https://doi.org/10.1016/j.ijrobp.2016.04.004 PMID: 27511845.